The history of copyright's flagship drug presents a interesting case for investors in the pharmaceutical sector. While initially a tremendous success, producing huge profits, the exclusivity lapse and the subsequent arrival of off-brand competitors have drastically affected income. This raises questions about the ongoing profitability of similar dr